arrow
P

Paul A. Cohen

Harry Perkins Institute of Medical Research
H指数:53
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Identifying therapeutic targets in low-grade serous ovarian carcinomas with no specific molecular profile

低级别浆液性卵巢癌中缺乏特定分子谱的治疗靶点识别

2026-05-010
PRE
Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma

BRCA缺陷性输卵管卵巢高级别浆液性癌的生存临床病理及分子预测因子

2026-04-010
OAAI
Cervical screening approach of self-collection, point-of-care HPV testing, and same-day colposcopy among Aboriginal and Torres Strait Islander women in remote Western Australia (the PREVENT Project): an implementation study

自我采集样本、即时HPV检测和当日阴道镜检查在澳大利亚西部偏远地区原住民和托雷斯海峡岛民女性中的宫颈癌筛查方法(PREVENT项目):一项实施研究

2025-08-080
OAAI
Exome sequencing identifies HELB as a novel susceptibility gene for non-mucinous, non-high-grade-serous epithelial ovarian cancer
2025-02-120
OAAI
Spatial transcriptomics reveals discrete tumour microenvironments and autocrine loops within ovarian cancer subclones
2024-04-039
OAAI
Shifting incidence and survival of epithelial ovarian cancer (1995-2014): A SurvMark-2 study
2023-01-238
OA
CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study

CCNE1与输卵管卵巢高级别浆液性癌患者的生存: 卵巢肿瘤组织分析联盟研究

CANCER
IF5.1
2022-12-2614
OAAI
Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2022-10-0711
OAAI
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma

MCM3是一种与输卵管卵巢高级别浆液性癌患者生存期延长相关的新型增殖标志物

2021-11-1510
OA